BERKELEY, CA (UroToday.com) - Prostate cancer is a major public health concern and is associated with significant healthcare costs.
It is the second most common malignancy in men, with 782,600 incident cases estimated globally in 2007. In the USA alone, an estimated 192,280 new cases of prostate cancer occurred in 2009, with 27,360 deaths.
With an estimated increase in the elderly population in the industrialized world from 400 million individuals > 65 years in 2000, to ≈ 1.5 billion by 2050, and an apparent increase in the 10-year relative survival rate of those diagnosed with prostate cancer, the economic burden of prostate cancer is predicted to increase markedly. Earlier detection through screening of serum PSA has been successful in identifying men who might benefit from treatment; as a result, many men are now diagnosed earlier and with lower-stage cancer than was previously the case, effectively increasing the economic burden of this disease. The present article aims to evaluate the cost of prostate cancer and its management in different countries...View or save the full text Mini Review as a .pdf file
Claus G. Roehrborn and Libby K. Black *
Department of Urology, UT Southwestern Medical Center, Dallas, TX , and * GlaxoSmithKline, Research Triangle Park, NC, USA
More BJUI Mini Reviews and Archives
